CPRX - Catalyst Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.3000
-0.2600 (-5.70%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.5600
Open4.5400
Bid0.0000 x 3100
Ask0.0000 x 3100
Day's Range4.2400 - 4.5500
52 Week Range1.8500 - 7.6700
Volume2525620
Avg. Volume2,524,215
Market Cap449M
Beta (3Y Monthly)2.39
PE Ratio (TTM)46.74
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Thomson Reuters StreetEvents

    Edited Transcript of CPRX earnings conference call or presentation 13-Nov-19 1:30pm GMT

    Q3 2019 Catalyst Pharmaceuticals Inc Earnings Call

  • Catalyst Focuses on Firdapse Label Expansion Amid Competition
    Zacks

    Catalyst Focuses on Firdapse Label Expansion Amid Competition

    Catalyst (CPRX) focuses on the development of Firdapse for additional indications.

  • Catalyst's (CPRX) Q3 Earnings Beat Estimates, Sales Miss
    Zacks

    Catalyst's (CPRX) Q3 Earnings Beat Estimates, Sales Miss

    Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2019.

  • Catalyst Pharmaceutical (CPRX) Beats Q3 Earnings Estimates
    Zacks

    Catalyst Pharmaceutical (CPRX) Beats Q3 Earnings Estimates

    Catalyst (CPRX) delivered earnings and revenue surprises of 18.18% and -8.51%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • 3 ‘Strong Buy’ Stocks to Buy on Weakness
    TipRanks

    3 ‘Strong Buy’ Stocks to Buy on Weakness

    Investors are constantly searching for the next big winner. We mean the stocks that are on track to see explosive growth, handsomely rewarding the investors that managed to get onboard at the right time. But how are investors supposed to know when it’s time to snap up the right stock?When first approaching this task, investors will often turn to names during or on the heels of an impressive rally. However, Wall Street analysts note that this isn’t always the best move. Instead, the Street’s seasoned pros tell investors that compelling investments can be found among names that have stumbled lately. Rockiness in share prices can present a unique opportunity to get in on the action before the stock heats up.Taking this into consideration, we used TipRanks’ Stock Screener tool to pinpoint 3 tickers with strong growth narratives that remain intact despite recent weakness. If this wasn’t promising enough, each of the names has received enough bullish calls in the last three months to be given a “Strong Buy” consensus rating.Enphase Energy (ENPH)Investors are desperately trying to understand what’s going on with Enphase Energy. Known for being the leading provider of solar microinverters, the company has seen shares tank following a period of massive growth in the first half of the year. Nonetheless, one analyst states that concerns regarding ENPH have been blown out of proportion.Roth Capital’s Philip Shen points to a report published by Jcap as the partial source of recent shakiness. The primary assumption made in the report is that ENPH has seven months of inventory left in the channel. Shen responded by calling this claim “simply nonsensical”, with his estimates putting the actual inventory levels at 3-4 weeks.Adding to the good news, the analyst wrote in a note to clients that the U.S. residential market is expanding much more quickly than previously expected.“We continue to believe the U.S. resi market will be up 25% YoY in 2019 AND in 2020 vs. consensus view of mid-teens YoY growth after a fresh round of checks this week. Overall, ENPH is ramping capacity at the right time to grow with an accelerating market,” the analyst commented.As a result, Shen advocates buying the dip in ENPH shares, as reiterates a Buy rating along with $30 price target, which implies shares could soar 65% in the next twelve months. (To watch Shen’s track record, click here)Like Shen, other Wall Street analysts are impressed with the energy tech company. As ENPH has earned 100% analyst support over the last three months, the word on the Street is that it’s a ‘Strong Buy’. Additionally, its $31.29 average price target indicates about 70% upside potential. (See Enphase stock analysis on TipRanks)Ciena Corporation (CIEN)Ciena supplies telecommunications networking equipment and software as well as provides various services. While it’s no question that shares have taken a beating over the last three months, several analysts maintain that big gains are in store.The company is on track to meet its full-year 2020 revenue and margin guidance thanks to its continued focus on revenue diversification. This diversification has been witnessed not only across geographic regions, but also across customer segments.On top of this, CIEN has successfully taken market share, becoming one of the top two players in the optical systems space. The other giant in the industry, Huawei, has been crippled given the fact that it’s still on the U.S. Commerce Department’s entry list, preventing the company from accessing the U.S. supply chain.This lends itself to Cowen & Co. analyst Paul Silverstein’s conclusion that the pullback represents an attractive entry point. “Significant broad-based rev diversification, ongoing share gains and focus on profitability, not just rev growth, is driving far better and more consistent, earnings power and cash flow. Investor expectations have yet to catch-up making for highly attractive risk-reward,” he explained. With this in mind, the five-star analyst remains bullish on CIEN. He even sees upside potential of 47%. (To watch Silverstein’s track record, click here)In general, the rest of the Street is also in favor of CIEN. 11 Buy ratings and 3 Holds assigned in the last three months add up to a ‘Strong Buy’ analyst consensus. At an average price target of $50.67, the potential twelve month gain comes in at 36%. (See Ciena stock analysis on TipRanks)Catalyst Pharmaceuticals (CPRX)Catalyst is a biopharma name that develops treatments for people affected by neuromuscular and neurological diseases including Lambert-Eaton myasthenic syndrome (LEMS), MuSK antibody positive myasthenia gravis (MuSK-MG), congenital myasthenic syndromes (CMS) and spinal muscular atrophy (SMA) Type 3.Analysts remind investors to look past recent weakness as its Firdapse drug, its FDA-approved therapy for LEMS in adults, still has the potential to heal share prices. Share prices are hurting partly as a result of unfavorable clinical data.On October 30, CPRX broke the news that Firdapse fell short of its primary endpoints during the Phase 3 CMS-001 study evaluating its ability to treat CMS, a group of conditions known for causing muscle weakness. Even though shares fell 13% in reaction to the findings, SunTrust Robinson analyst Edward Nash points out that this result was somewhat expected. “We are not surprised by the results give more than 50 subtypes of CMS with only 16 pts randomized in the study,” he commented.The four-star analyst adds that the drug is likely to demonstrate improved performance in treating MuSK-MG, which is set to see study enrollment completion by the end of the year. This would make top line data available in the first half of 2020, possibly driving big gains for CPRX.With Nash noting that the FDA could take a favorable stance on CPRX due to the difficult nature of the patient population, it’s no wonder he reiterated his bullish recommendation and $11 price target. This target conveys his confidence in CPRX’s ability to climb 135% higher over the next twelve months. (To watch Nash’s track record, click here)As 4 Buy ratings have been issued in the previous three months compared to no Holds or Sells, CPRX is a ‘Strong Buy’. In addition, the biopharma’s $9 average price target brings the upside potential to 91%. (See CPRX stock analysis on TipRanks)

  • Investors Can Find Strong Stocks with our First Profit Screen
    Zacks

    Investors Can Find Strong Stocks with our First Profit Screen

    Investors Can Find Strong Stocks with our First Profit Screen

  • Catalyst Pharma (CPRX) to Post Q3 Earnings: What's in Store?
    Zacks

    Catalyst Pharma (CPRX) to Post Q3 Earnings: What's in Store?

    During Catalyst's (CPRX) third-quarter 2019 conference call, investor focus will be on the sales performance of its only marketed drug Firdapse and its label expansion studies.

  • Did The Underlying Business Drive Catalyst Pharmaceuticals's (NASDAQ:CPRX) Lovely 416% Share Price Gain?
    Simply Wall St.

    Did The Underlying Business Drive Catalyst Pharmaceuticals's (NASDAQ:CPRX) Lovely 416% Share Price Gain?

    Generally speaking, investors are inspired to be stock pickers by the potential to find the big winners. But when you...

  • GuruFocus.com

    Top Insider Buys Highlight for the Week of Oct. 18

    Insiders invest in Catalyst Pharmaceuticals, Keurig Dr Pepper, Hersha Hospitality Trust and Jernigan Capital Continue reading...

  • Learn How to Find Top-Ranked 'Cheap' Stocks Under $10 with this Screener
    Zacks

    Learn How to Find Top-Ranked 'Cheap' Stocks Under $10 with this Screener

    Learn How to Find Top-Ranked 'Cheap' Stocks Under $10 with this Screener

  • Should You Wait Before Investing In Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)?
    Simply Wall St.

    Should You Wait Before Investing In Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)?

    As the US$673m market cap Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released another year of negative earnings...

  • Buy These 7 Small Drugmakers to Boost Your Portfolio's Health
    Zacks

    Buy These 7 Small Drugmakers to Boost Your Portfolio's Health

    Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.

  • Catalyst Pharmaceutical (CPRX) is a Great Momentum Stock: Should You Buy?
    Zacks

    Catalyst Pharmaceutical (CPRX) is a Great Momentum Stock: Should You Buy?

    Does Catalyst Pharmaceutical (CPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • Implied Volatility Surging for Catalyst (CPRX) Stock Options
    Zacks

    Implied Volatility Surging for Catalyst (CPRX) Stock Options

    Investors need to pay close attention to Catalyst (CPRX) stock based on the movements in the options market lately.

  • Benzinga

    The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 11) Ardelyx Inc (NASDAQ: ARDX ) Avedro Inc (NASDAQ: AVDR ...

  • Investors Can Find Big Returns with this First Profit Screen
    Zacks

    Investors Can Find Big Returns with this First Profit Screen

    Investors Can Find Big Returns with this First Profit Screen

  • Thomson Reuters StreetEvents

    Edited Transcript of CPRX earnings conference call or presentation 8-Aug-19 12:30pm GMT

    Q2 2019 Catalyst Pharmaceuticals Inc Earnings Call

  • Why Is Catalyst (CPRX) Up 23% Since Last Earnings Report?
    Zacks

    Why Is Catalyst (CPRX) Up 23% Since Last Earnings Report?

    Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Catalyst Pharmaceuticals (CPRX) Looks Good: Stock Adds 6% in Session
    Zacks

    Catalyst Pharmaceuticals (CPRX) Looks Good: Stock Adds 6% in Session

    Catalyst Pharmaceuticals (CPRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

  • Here's How to Find Top-Ranked Stocks Under $10 to Buy
    Zacks

    Here's How to Find Top-Ranked Stocks Under $10 to Buy

    Here's How to Find Top-Ranked Stocks Under $10 to Buy

  • Top Ranked Momentum Stocks to Buy for August 19th
    Zacks

    Top Ranked Momentum Stocks to Buy for August 19th

    Top Ranked Momentum Stocks to Buy for August 19th

  • Will Catalyst Pharmaceuticals Continue to Surge Higher?
    Zacks

    Will Catalyst Pharmaceuticals Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor Catalyst Pharmaceuticals.

  • Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): The Best Of Both Worlds
    Simply Wall St.

    Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): The Best Of Both Worlds

    Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on...

  • Why Catalyst Pharmaceuticals Stock Broke Down Today
    Motley Fool

    Why Catalyst Pharmaceuticals Stock Broke Down Today

    Catalyst's shares took a sizable hit this morning.

  • Catalyst's (CPRX) Q2 Earnings and Revenues Beat Estimates
    Zacks

    Catalyst's (CPRX) Q2 Earnings and Revenues Beat Estimates

    Catalyst (CPRX) surpasses earnings and sales estimates in the second quarter of 2019.